| Popis: |
Jemperli (dostarlimab) is an anti-PD-1 mab used to treat endometrial cancer. It is a humanized mab produced using rdna technology in CHO cells. It is approved in the US and EU and was developed by Tesaro, later acquired by GlaxoSmithKline. Clinical trial data on dostarlimab was reviewed using online sources such as PubMed, Cochrane, and Medscape. The review included English language clinical trials, randomized trials, original articles, newsletters, and letters to the editor. Results from the GARNET clinical trial an open-label, multicohort study, which showed reduced progression and recurrence of cancer in treated individuals, led to the approval of dostarlimab. In some cases, the cancer was undetectable during imaging scans during treatment with the drug. Keywords: Jemperli, Dostarlimab, Anti-PD-1, GARNET clinical trial, Treatment, Endometrial cancer treatment, Cancer therapy. |
